Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women.
Journal of internal medicine • Vol. 251, Issue 3 • 2002
Endometrial safety of continuous combined hormone replacement therapy with 17beta-oestradiol (1 or 2 mg) and dydrogesterone.
Maturitas • Vol. 37, Issue 3 • 2001
Analysis of the contribution of dydrogesterone to bone turnover changes in postmenopausal women commencing hormone replacement therapy.
The Journal of clinical endocrinology and metabolism • Vol. 86, Issue 3 • 2001
Effects of 15 months of 17 beta-estradiol and dydrogesterone on systolic cardiac function according to quantitative and Doppler echocardiography in healthy postmenopausal women.
American journal of obstetrics and gynecology • Vol. 184, Issue 5 • 2001
